Myriad Genetics Inc focuses on molecular diagnostic testing for disease risk assessment and treatment guidance. Insider transactions reveal selling trend, with recent sale by Dale Muzzey. Stock priced at $26.17, slightly overvalued based on GF Value of $23.47/share.